+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antibody-drug Conjugates for Tumors Market - Global Forecast 2025-2030- Product Image
Antibody-drug Conjugates for Tumors Market - Global Forecast 2025-2030- Product Image
Sale

Antibody-drug Conjugates for Tumors Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 192 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6136458
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Antibody-drug conjugates (ADCs) represent a significant advancement in precision oncology, enabling targeted delivery of cytotoxic agents to tumor cells while limiting impact on healthy tissues. The rapidly evolving ADC market is shaped by biotechnology innovation, regulatory adaptations, global competition, and new supply chain considerations, positioning stakeholders to capitalize on a range of opportunities and regional dynamics.

Market Snapshot: Antibody-Drug Conjugate Market Overview

The ADC market is experiencing robust growth, reflected in increasing investment, regulatory approvals across multiple tumor types, and an expanding clinical pipeline. Advances in antibody engineering, linker stability, and drug conjugation technologies have driven development and commercial momentum. As adoption broadens to both hematologic and solid tumors, senior decision-makers monitor shifting patterns in regulatory access, manufacturing strategy, and reimbursement to maximize market positioning and operational resilience.

Scope & Segmentation of the ADC Market

This research provides a comprehensive analysis of the ADC industry ecosystem, mapping innovation, regional expansion, and commercial strategies across all major segments and platforms. The study explores:

  • Tumor Type: Breast, lung, lymphoma, ovarian, and other malignancies with variable expression profiles guiding antigen targeting and therapeutic design.
  • Payload Type: Auristatins (MMAE, MMAF), calicheamicin, duocarmycin, maytansinoids (DM1, DM4), each facilitating tailored cytotoxicity and response to resistance mechanisms.
  • Conjugation Method: Cysteine, lysine, engineered cysteine, and enzymatic approaches supporting optimized antibody integrity and payload loading.
  • Linker Type: Cleavable (acid-cleavable, protease-cleavable) and noncleavable chemistries designed for specific activation within tumor environments.
  • Molecular Target: CD30, CD33, HER2, and additional antigens defining efficacy profiles and safety parameters.
  • Line Of Therapy: Placement in first line, second line, and refractory treatment settings for better patient outcomes.
  • Distribution Channel: Hospital, retail, and specialty pharmacy networks managing inpatient and outpatient ADC delivery.
  • Antibody Class: IgG1, IgG2, and IgG4 influencing immune effector function and half-life profile.
  • Geographic Coverage: Americas (including United States, Canada, Brazil), EMEA (United Kingdom, Germany, France, Middle East, Africa), and Asia-Pacific (China, India, Japan, South Korea, Australia, Southeast Asian countries).
  • Industry Innovators: Comprehensive assessment of Seagen Inc., F. Hoffmann-La Roche Ltd., Daiichi Sankyo Company, Pfizer Inc., AstraZeneca PLC, and ImmunoGen, Inc.

Key Takeaways for Senior Leaders

  • Technological progress in site-specific conjugation and next-generation payloads is fueling differentiated clinical value and improving ADC safety profiles in diverse tumor classes.
  • Strategic collaborations between biopharma, CDMOs, and academic partners accelerate proof-of-concept and boost manufacturing resilience across regional production hubs.
  • Emerging digital solutions in biomarker discovery and patient stratification are optimizing clinical trial designs, enhancing both trial efficiency and regulatory engagement.
  • Regional differences shape ADC access through local manufacturing, regulatory harmonization, and targeted supply chain investments in North America, EMEA, and Asia-Pacific.
  • Portfolio management is evolving, with industry leaders focusing on unique targets, antibody formats, and integrated value chains to maintain competitive advantage.
  • Emphasis on early health authority dialogue, adaptive trial methods, and real-world evidence gathering is shortening timelines to approval and market adoption.

Tariff Impact and Supply Chain Adaptation

The 2025 US tariff regime on pharmaceutical ingredients has increased costs for ADC components like cytotoxic payload precursors and conjugation reagents. Companies are diversifying supply chains, evaluating onshore synthesis, and establishing regional manufacturing hubs to manage exposure. These strategies strengthen local capacity while maintaining early-stage development momentum via targeted exemptions and long-term supplier agreements.

Methodology & Data Sources for ADC Market Intelligence

This analysis deploys a blend of primary research, including structured interviews with key industry experts, and secondary research from peer-reviewed literature and government databases. Triangulation of qualitative and quantitative data ensures robust, unbiased conclusions tailored for stakeholders navigating the evolving ADC landscape.

Why This Report Matters

  • Strategic insight enables precise portfolio and pipeline management for enhanced value creation in the antibody-drug conjugate market.
  • Regional analysis empowers informed decisions on investment, alliance formation, and market entry in high-growth geographies.
  • Companies gain a competitive edge by understanding technological evolution, tariff-driven supply chain shifts, and best practices for commercialization.

Conclusion

The ADC market is advancing through a confluence of scientific innovation, regional growth, and adaptive industry strategies. Decision-makers equipped with this evidence-based intelligence are primed to optimize investment and seize emerging opportunities in precision oncology.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Integration of site-specific conjugation technologies to enhance ADC homogeneity and therapeutic index
5.2. Exploration of novel PBD dimer cytotoxic payloads to improve ADC potency and reduce systemic toxicity
5.3. Development of bispecific ADC constructs targeting dual tumor antigens to overcome heterogeneity
5.4. Implementation of biomarker-driven patient stratification strategies to optimize ADC clinical efficacy
5.5. Adoption of next-generation cleavable linkers to minimize off-target release and enhance therapeutic window
5.6. Strategic collaborations between biopharma firms and CDMOs to accelerate ADC manufacturing scale-up and supply
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Antibody-drug Conjugates for Tumors Market, by Tumor Type
8.1. Introduction
8.2. Breast
8.3. Lung
8.4. Lymphoma
8.5. Ovarian
9. Antibody-drug Conjugates for Tumors Market, by Payload Type
9.1. Introduction
9.2. Auristatin
9.2.1. MMAE
9.2.2. MMAF
9.3. Calicheamicin
9.4. Duocarmycin
9.5. Maytansinoid
9.5.1. DM1
9.5.2. DM4
10. Antibody-drug Conjugates for Tumors Market, by Conjugation Method
10.1. Introduction
10.2. Cysteine
10.3. Lysine
10.4. Site Specific
10.4.1. Engineered Cysteine
10.4.2. Enzymatic
11. Antibody-drug Conjugates for Tumors Market, by Linker Type
11.1. Introduction
11.2. Cleavable
11.2.1. Acid Cleavable
11.2.2. Protease Cleavable
11.3. Noncleavable
12. Antibody-drug Conjugates for Tumors Market, by Molecular Target
12.1. Introduction
12.2. CD30
12.3. CD33
12.4. HER2
13. Antibody-drug Conjugates for Tumors Market, by Line Of Therapy
13.1. Introduction
13.2. First Line
13.3. Second Line
13.4. Third Line Or Later
14. Antibody-drug Conjugates for Tumors Market, by Distribution Channel
14.1. Introduction
14.2. Hospital Pharmacy
14.3. Retail Pharmacy
14.4. Specialty Pharmacy
15. Antibody-drug Conjugates for Tumors Market, by Antibody Class
15.1. Introduction
15.2. IgG1
15.3. IgG2
15.4. IgG4
16. Americas Antibody-drug Conjugates for Tumors Market
16.1. Introduction
16.2. United States
16.3. Canada
16.4. Mexico
16.5. Brazil
16.6. Argentina
17. Europe, Middle East & Africa Antibody-drug Conjugates for Tumors Market
17.1. Introduction
17.2. United Kingdom
17.3. Germany
17.4. France
17.5. Russia
17.6. Italy
17.7. Spain
17.8. United Arab Emirates
17.9. Saudi Arabia
17.10. South Africa
17.11. Denmark
17.12. Netherlands
17.13. Qatar
17.14. Finland
17.15. Sweden
17.16. Nigeria
17.17. Egypt
17.18. Turkey
17.19. Israel
17.20. Norway
17.21. Poland
17.22. Switzerland
18. Asia-Pacific Antibody-drug Conjugates for Tumors Market
18.1. Introduction
18.2. China
18.3. India
18.4. Japan
18.5. Australia
18.6. South Korea
18.7. Indonesia
18.8. Thailand
18.9. Philippines
18.10. Malaysia
18.11. Singapore
18.12. Vietnam
18.13. Taiwan
19. Competitive Landscape
19.1. Market Share Analysis, 2024
19.2. FPNV Positioning Matrix, 2024
19.3. Competitive Analysis
19.3.1. Seagen Inc.
19.3.2. F. Hoffmann-La Roche Ltd.
19.3.3. Daiichi Sankyo Company, Limited
19.3.4. Pfizer Inc.
19.3.5. AstraZeneca PLC
19.3.6. ImmunoGen, Inc.
20. ResearchAI21. ResearchStatistics22. ResearchContacts23. ResearchArticles24. Appendix
List of Figures
FIGURE 1. ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY TUMOR TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY TUMOR TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY PAYLOAD TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY PAYLOAD TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY CONJUGATION METHOD, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY CONJUGATION METHOD, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY LINKER TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY LINKER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY MOLECULAR TARGET, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY MOLECULAR TARGET, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 18. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY ANTIBODY CLASS, 2024 VS 2030 (%)
FIGURE 20. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY ANTIBODY CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 31. ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET: RESEARCHAI
FIGURE 32. ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET: RESEARCHSTATISTICS
FIGURE 33. ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET: RESEARCHCONTACTS
FIGURE 34. ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY BREAST, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY BREAST, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY LUNG, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY LUNG, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY OVARIAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY OVARIAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY PAYLOAD TYPE, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY PAYLOAD TYPE, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY AURISTATIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY AURISTATIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY MMAE, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY MMAE, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY MMAF, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY MMAF, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY AURISTATIN, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY AURISTATIN, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY CALICHEAMICIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY CALICHEAMICIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY DUOCARMYCIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY DUOCARMYCIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY MAYTANSINOID, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY MAYTANSINOID, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY DM1, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY DM1, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY DM4, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY DM4, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY MAYTANSINOID, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY MAYTANSINOID, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY CONJUGATION METHOD, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY CONJUGATION METHOD, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY CYSTEINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY CYSTEINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY LYSINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY LYSINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY SITE SPECIFIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY SITE SPECIFIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY ENGINEERED CYSTEINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY ENGINEERED CYSTEINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY ENZYMATIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY ENZYMATIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY SITE SPECIFIC, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY SITE SPECIFIC, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY LINKER TYPE, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY LINKER TYPE, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY CLEAVABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY CLEAVABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY ACID CLEAVABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY ACID CLEAVABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY PROTEASE CLEAVABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY PROTEASE CLEAVABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY CLEAVABLE, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY CLEAVABLE, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY NONCLEAVABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY NONCLEAVABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY MOLECULAR TARGET, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY MOLECULAR TARGET, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY CD30, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY CD30, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY CD33, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY CD33, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY HER2, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY HER2, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY THIRD LINE OR LATER, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY THIRD LINE OR LATER, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY ANTIBODY CLASS, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY ANTIBODY CLASS, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY IGG1, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY IGG1, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY IGG2, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY IGG2, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY IGG4, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY IGG4, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY PAYLOAD TYPE, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY PAYLOAD TYPE, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY AURISTATIN, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY AURISTATIN, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY MAYTANSINOID, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY MAYTANSINOID, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY CONJUGATION METHOD, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY CONJUGATION METHOD, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY SITE SPECIFIC, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY SITE SPECIFIC, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY LINKER TYPE, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY LINKER TYPE, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY CLEAVABLE, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY CLEAVABLE, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY MOLECULAR TARGET, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY MOLECULAR TARGET, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY ANTIBODY CLASS, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY ANTIBODY CLASS, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY PAYLOAD TYPE, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY PAYLOAD TYPE, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY AURISTATIN, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY AURISTATIN, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY MAYTANSINOID, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY MAYTANSINOID, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY CONJUGATION METHOD, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY CONJUGATION METHOD, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY SITE SPECIFIC, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY SITE SPECIFIC, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY LINKER TYPE, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY LINKER TYPE, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY CLEAVABLE, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY CLEAVABLE, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY MOLECULAR TARGET, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY MOLECULAR TARGET, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY ANTIBODY CLASS, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY ANTIBODY CLASS, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 151. CANADA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
TABLE 152. CANADA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
TABLE 153. CANADA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY PAYLOAD TYPE, 2018-2024 (USD MILLION)
TABLE 154. CANADA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY PAYLOAD TYPE, 2025-2030 (USD MILLION)
TABLE 155. CANADA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY AURISTATIN, 2018-2024 (USD MILLION)
TABLE 156. CANADA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY AURISTATIN, 2025-2030 (USD MILLION)
TABLE 157. CANADA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY MAYTANSINOID, 2018-2024 (USD MILLION)
TABLE 158. CANADA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY MAYTANSINOID, 2025-2030 (USD MILLION)
TABLE 159. CANADA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY CONJUGATION METHOD, 2018-2024 (USD MILLION)
TABLE 160. CANADA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY CONJUGATION METHOD, 2025-2030 (USD MILLION)
TABLE 161. CANADA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY SITE SPECIFIC, 2018-2024 (USD MILLION)
TABLE 162. CANADA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY SITE SPECIFIC, 2025-2030 (USD MILLION)
TABLE 163. CANADA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY LINKER TYPE, 2018-2024 (USD MILLION)
TABLE 164. CANADA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY LINKER TYPE, 2025-2030 (USD MILLION)
TABLE 165. CANADA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY CLEAVABLE, 2018-2024 (USD MILLION)
TABLE 166. CANADA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY CLEAVABLE, 2025-2030 (USD MILLION)
TABLE 167. CANADA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY MOLECULAR TARGET, 2018-2024 (USD MILLION)
TABLE 168. CANADA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY MOLECULAR TARGET, 2025-2030 (USD MILLION)
TABLE 169. CANADA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 170. CANADA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 171. CANADA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 172. CANADA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 173. CANADA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY ANTIBODY CLASS, 2018-2024 (USD MILLION)
TABLE 174. CANADA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY ANTIBODY CLASS, 2025-2030 (USD MILLION)
TABLE 175. MEXICO ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
TABLE 176. MEXICO ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
TABLE 177. MEXICO ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY PAYLOAD TYPE, 2018-2024 (USD MILLION)
TABLE 178. MEXICO ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY PAYLOAD TYPE, 2025-2030 (USD MILLION)
TABLE 179. MEXICO ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY AURISTATIN, 2018-2024 (USD MILLION)
TABLE 180. MEXICO ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY AURISTATIN, 2025-2030 (USD MILLION)
TABLE 181. MEXICO ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY MAYTANSINOID, 2018-2024 (USD MILLION)
TABLE 182. MEXICO ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY MAYTANSINOID, 2025-2030 (USD MILLION)
TABLE 183. MEXICO ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY CONJUGATION METHOD, 2018-2024 (USD MILLION)
TABLE 184. MEXICO ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY CONJUGATION METHOD, 2025-2030 (USD MILLION)
TABLE 185. MEXICO ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY SITE SPECIFIC, 2018-2024 (USD MILLION)
TABLE 186. MEXICO ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY SITE SPECIFIC, 2025-2030 (USD MILLION)
TABLE 187. MEXICO ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY LINKER TYPE, 2018-2024 (USD MILLION)
TABLE 188. MEXICO ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY LINKER TYPE, 2025-2030 (USD MILLION)
TABLE 189. MEXICO ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY CLEAVABLE, 2018-2024 (USD MILLION)
TABLE 190. MEXICO ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY CLEAVABLE, 2025-2030 (USD MILLION)
TABLE 191. MEXICO ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY MOLECULAR TARGET, 2018-2024 (USD MILLION)
TABLE 192. MEXICO ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY MOLECULAR TARGET, 2025-2030 (USD MILLION)
TABLE 193. MEXICO ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 194. MEXICO ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 195. MEXICO ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 196. MEXICO ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 197. MEXICO ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY ANTIBODY CLASS, 2018-2024 (USD MILLION)
TABLE 198. MEXICO ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY ANTIBODY CLASS, 2025-2030 (USD MILLION)
TABLE 199. BRAZIL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
TABLE 200. BRAZIL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
TABLE 201. BRAZIL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY PAYLOAD TYPE, 2018-2024 (USD MILLION)
TABLE 202. BRAZIL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY PAYLOAD TYPE, 2025-2030 (USD MILLION)
TABLE 203. BRAZIL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY AURISTATIN, 2018-2024 (USD MILLION)
TABLE 204. BRAZIL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY AURISTATIN, 2025-2030 (USD MILLION)
TABLE 205. BRAZIL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY MAYTANSINOID, 2018-2024 (USD MILLION)
TABLE 206. BRAZIL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY MAYTANSINOID, 2025-2030 (USD MILLION)
TABLE 207. BRAZIL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY CONJUGATION METHOD, 2018-2024 (USD MILLION)
TABLE 208. BRAZIL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY CONJUGATION METHOD, 2025-2030 (USD MILLION)
TABLE 209. BRAZIL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY SITE SPECIFIC, 2018-2024 (USD MILLION)
TABLE 210. BRAZIL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY SITE SPECIFIC, 2025-2030 (USD MILLION)
TABLE 211. BRAZIL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY LINKER TYPE, 2018-2024 (USD MILLION)
TABLE 212. BRAZIL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY LINKER TYPE, 2025-2030 (USD MILLION)
TABLE 213. BRAZIL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY CLEAVABLE, 2018-2024 (USD MILLION)
TABLE 214. BRAZIL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY CLEAVABLE, 2025-2030 (USD MILLION)
TABLE 215. BRAZIL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY MOLECULAR TARGET, 2018-2024 (USD MILLION)
TABLE 216. BRAZIL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY MOLECULAR TARGET, 2025-2030 (USD MILLION)
TABLE 217. BRAZIL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 218. BRAZIL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 219. BRAZIL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 220. BRAZIL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 221. BRAZIL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY ANTIBODY CLASS, 2018-2024 (USD MILLION)
TABLE 222. BRAZIL ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY ANTIBODY CLASS, 2025-2030 (USD MILLION)
TABLE 223. ARGENTINA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
TABLE 224. ARGENTINA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
TABLE 225. ARGENTINA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY PAYLOAD TYPE, 2018-2024 (USD MILLION)
TABLE 226. ARGENTINA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY PAYLOAD TYPE, 2025-2030 (USD MILLION)
TABLE 227. ARGENTINA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY AURISTATIN, 2018-2024 (USD MILLION)
TABLE 228. ARGENTINA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY AURISTATIN, 2025-2030 (USD MILLION)
TABLE 229. ARGENTINA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY MAYTANSINOID, 2018-2024 (USD MILLION)
TABLE 230. ARGENTINA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY MAYTANSINOID, 2025-2030 (USD MILLION)
TABLE 231. ARGENTINA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY CONJUGATION METHOD, 2018-2024 (USD MILLION)
TABLE 232. ARGENTINA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY CONJUGATION METHOD, 2025-2030 (USD MILLION)
TABLE 233. ARGENTINA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY SITE SPECIFIC, 2018-2024 (USD MILLION)
TABLE 234. ARGENTINA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY SITE SPECIFIC, 2025-2030 (USD MILLION)
TABLE 235. ARGENTINA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY LINKER TYPE, 2018-2024 (USD MILLION)
TABLE 236. ARGENTINA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY LINKER TYPE, 2025-2030 (USD MILLION)
TABLE 237. ARGENTINA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY CLEAVABLE, 2018-2024 (USD MILLION)
TABLE 238. ARGENTINA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY CLEAVABLE, 2025-2030 (USD MILLION)
TABLE 239. ARGENTINA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY MOLECULAR TARGET, 2018-2024 (USD MILLION)
TABLE 240. ARGENTINA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY MOLECULAR TARGET, 2025-2030 (USD MILLION)
TABLE 241. ARGENTINA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 242. ARGENTINA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 243. ARGENTINA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 244. ARGENTINA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 245. ARGENTINA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY ANTIBODY CLASS, 2018-2024 (USD MILLION)
TABLE 246. ARGENTINA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY ANTIBODY CLASS, 2025-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY PAYLOAD TYPE, 2018-2024 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY PAYLOAD TYPE, 2025-2030 (USD MILLION)
TABLE 251. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY AURISTATIN, 2018-2024 (USD MILLION)
TABLE 252. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY AURISTATIN, 2025-2030 (USD MILLION)
TABLE 253. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY MAYTANSINOID, 2018-2024 (USD MILLION)
TABLE 254. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY MAYTANSINOID, 2025-2030 (USD MILLION)
TABLE 255. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY CONJUGATION METHOD, 2018-2024 (USD MILLION)
TABLE 256. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY CONJUGATION METHOD, 2025-2030 (USD MILLION)
TABLE 257. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY SITE SPECIFIC, 2018-2024 (USD MILLION)
TABLE 258. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY SITE SPECIFIC, 2025-2030 (USD MILLION)
TABLE 259. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY LINKER TYPE, 2018-2024 (USD MILLION)
TABLE 260. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY LINKER TYPE, 2025-2030 (USD MILLION)
TABLE 261. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY CLEAVABLE, 2018-2024 (USD MILLION)
TABLE 262. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY CLEAVABLE, 2025-2030 (USD MILLION)
TABLE 263. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY MOLECULAR TARGET, 2018-2024 (USD MILLION)
TABLE 264. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY MOLECULAR TARGET, 2025-2030 (USD MILLION)
TABLE 265. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 266. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 267. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 268. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 269. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY ANTIBODY CLASS, 2018-2024 (USD MILLION)
TABLE 270. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY ANTIBODY CLASS, 2025-2030 (USD MILLION)
TABLE 271. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 272. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 273. UNITED KINGDOM ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
TABLE 274. UNITED KINGDOM ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
TABLE 275. UNITED KINGDOM ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY PAYLOAD TYPE, 2018-2024 (USD MILLION)
TABLE 276. UNITED KINGDOM ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY PAYLOAD TYPE, 2025-2030 (USD MILLION)
TABLE 277. UNITED KINGDOM ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY AURISTATIN, 2018-2024 (USD MILLION)
TABLE 278. UNITED KINGDOM ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY AURISTATIN, 2025-2030 (USD MILLION)
TABLE 279. UNITED KINGDOM ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY MAYTANSINOID, 2018-2024 (USD MILLION)
TABLE 280. UNITED KINGDOM ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY MAYTANSINOID, 2025-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY CONJUGATION METHOD, 2018-2024 (USD MILLION)
TABLE 282. UNITED KINGDOM ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY CONJUGATION METHOD, 2025-2030 (USD MILLION)
TABLE 283. UNITED KINGDOM ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY SITE SPECIFIC, 2018-2024 (USD MILLION)
TABLE 284. UNITED KINGDOM ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY SITE SPECIFIC, 2025-2030 (USD MILLION)
TABLE 285. UNITED KINGDOM ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY LINKER TYPE, 2018-2024 (USD MILLION)
TABLE 286. UNITED KINGDOM ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY LINKER TYPE, 2025-2030 (USD MILLION)
TABLE 287. UNITED KINGDOM ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY CLEAVABLE, 2018-2024 (USD MILLION)
TABLE 288. UNITED KINGDOM ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY CLEAVABLE, 2025-2030 (USD MILLION)
TABLE 289. UNITED KINGDOM ANTIBODY-DRUG CONJUGATES FOR TUMORS MARKET SIZE, BY MOLECULAR TARGET, 2018-2024 (USD MILLION)
TABLE 290. U

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Antibody-drug Conjugates for Tumors Market report include:
  • Seagen Inc.
  • F. Hoffmann-La Roche Ltd.
  • Daiichi Sankyo Company, Limited
  • Pfizer Inc.
  • AstraZeneca PLC
  • ImmunoGen, Inc.

Related Topics

Related Reports

Antibody Drug Conjugate Market - Global Forecast 2025-2030 - Product Image

Antibody Drug Conjugate Market - Global Forecast 2025-2030

  • Report
  • 188 Pages
  • Global
From
Antibody Drug Conjugate Market Industry Trends and Global Forecasts to 2035, by Target Disease Indication, Therapeutic Area, Linker, Payload, Target Antigens and Key Geographical Regions - Product Image

Antibody Drug Conjugate Market Industry Trends and Global Forecasts to 2035, by Target Disease Indication, Therapeutic Area, Linker, Payload, Target Antigens and Key Geographical Regions

  • Report
  • 716 Pages
  • Global
From
Antibody Drug Conjugate - Competitive Landscape, 2025 - Product Image

Antibody Drug Conjugate - Competitive Landscape, 2025

  • Report
  • 450 Pages
  • Global
From
Global Antibody Drug Conjugates Market - 2025-2035: Focus on Product, Application, Target, Payload Type, Linker Type, Linker Technology, and Geography - Product Image

Global Antibody Drug Conjugates Market - 2025-2035: Focus on Product, Application, Target, Payload Type, Linker Type, Linker Technology, and Geography

  • Report
  • Global
From
Cancer Antibody Drug Conjugates Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Cancer Antibody Drug Conjugates Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.